Non-Small Cell Lung Cancer Therapeutics Market to reach US$ 43,713.1 Mn, Growing Adoption of Targeted Therapy for Diagnosis to Boost the Market

1

• Non-Small Cell Lung Cancer Therapeutics Market
  2019 - Size, Growth Factors, Top Leaders,
  Development Strategy, Competitive Landscape and
  Regional Forecast 2025
• The Global Non-Small Cell Lung Cancer
  Therapeutics Market is growing impressively due
  to recent surge in adoption of targeted therapy
  for treating non-small cell lung cancer.
  According to a report published by Fortune
  Business Insights, titled Non-Small Cell Lung
  Cancer Therapeutics Global Market Analysis,
  Insights and Forecasts, 2019-2026, the market
  value will rise substantially from US 16,011.7
  Mn in 2018 to US 43,713.1 Mn by 2026.
• Fortune Business Insights has further predicted
  the market to exhibit an impressive CAGR of
  13.4 between 2019 and 2026 due to exceptional
  advancements in targeted therapy in recent
  years. Such high growth can be attributable to
  the increasing demand for chemotherapy and
  targeted therapy. Furthermore, advantages of
  targeted therapy over other alternatives are in
  plenty. Driven by this, the demand for targeted
  therapy for diagnosis will increase, which in
  turn spurs growth in the global non-small cell
  lung cancer therapeutics market.
• Sample PDF Brochure https//www.fortunebusinessins
  ights.com/enquiry/request-sample-
  pdf/non-small-cell-lung-cancer-therapeutics-market
  -100484
• Some of the key companies that are present in the
  Global Non-Small Cell Lung Cancer Therapeutics
  Market are
• Genentech (F. Hoffmann-La Roche Ltd)
• Eli Lilly and Company
• Celgene Corporation
• AstraZeneca
• Pfizer Inc.
• Sanofi
• Novartis AG
• Astellas
• Bristol Myers Squibb
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Millennium Pharmaceuticals, Inc. (Takeda)
• Merck Sharp Dohme Corp.

2

• biological therapies has been hugely beneficial
  in treating non-small cell lung cancer (NSCLC).
  Biological therapies have had a positive impact
  on the molecular subsets of various lung cancer
  categories. NSCLC treatments have been blessed
  with various advancements in biological therapy
  concepts and they are now playing a major part in
  minimizing symptoms of non-small cell lung
  cancer as well. Thus, the use of biological
  therapies had a positive impact on the global
  NSCLC therapeutics market and is likely to favour
  growth of this market in the forecast period.
• Major Table of Content Non-Small Cell Lung Cancer
  Therapeutics Market are
• Market Dynamics
• Market Drivers
• Market Restraints
• Market Opportunities
• Key Insights
• Prevalence of Non-Small Cell Lung Cancer by Type
• Regulatory Scenario by Key Regions
• Key Industry Developments
• Pipeline Analysis
• Overview of Current Advances in RD for NonSmall
  Cell Lung Cancer Therapeutics
• Adenocarcinoma to Emerge as The Leading Segment
• According to cancer.org, adenocarcinoma accounted
  for 40 of all lung cancers. Although prevalence
  of adenocarcinoma is high, it is the least deadly
  among all types of lung cancers. Adenocarcinoma
  allows for easy NSCLC prognosis as it can be
  detected at a very early stage. Furthermore,
  adenocarcinoma can be treated easily as they
  spread at a slower rate than other NSCLCs. High
  chances of diagnosis of adenocarcinoma is a major
  factor why adenocarcinoma will emerge as the
  leading segment in the forecast period, as well.
• Some of the leading companies that are operating
  in the global non-small cell lung cancer
  therapeutics market are Genentech (F. Hoffmann-La
  Roche Ltd), Eli Lilly and Company, Celgene
  Corporation, AstraZeneca, Pfizer Inc., Sanofi,
  Novartis AG, Astellas, Bristol Myers Squibb,
  Boehringer Ingelheim Pharmaceuticals, Inc.,
  Millennium Pharmaceuticals, Inc. (Takeda), Merck
  Sharp Dohme Corp. and others.
• Browse Complete Report Details at
  https//www.fortunebusinessinsights.com/industry-
  reports/non-small-cell-lung-cancer-therapeutics-m
  arket-100484